Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea
NCT ID: NCT01407848
Last Updated: 2015-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2012-01-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)
NCT02527798
Noninvasive Hemodynamics Assessment of Preterms With Successful Medical Closure of PDA
NCT06606015
Effects of Flow Magnitude on Cardiorespiratory Stability During Nasal High Flow Therapy in Preterm Infants
NCT05908227
Early Versus Routine Caffeine Administration in Extremely Preterm Neonates
NCT01783561
Alternative Paracetamol Treatments for the Neonate With a hsPDA
NCT03604796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The benefit will be measured as reduction of dyspnea, respiratory rate, oxygen demand and time on CPAP.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Furosemide
1 mg/kg/Ed
Furosemide
Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
Saline 0,9%
1ml/kg/Ed
Saline 0,9%
nebulised 0,9% saline 4x/d for max.3 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Furosemide
Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
Saline 0,9%
nebulised 0,9% saline 4x/d for max.3 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The need for CPAP \>6 h to obtain the oxygen saturation \>92%
* Written informed consent of parent/guardian
Exclusion Criteria
* Intubation and mechanical ventilation before Inclusion in the trail
* Malformation and any other several disease with disturb of respiratory
* Subjects participating in other clinical trials
6 Hours
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cologne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Patrizia Nitsch-Felsecker
Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bernhard Roth, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University Cologne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children´s Hospital University of Cologne
Cologne, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-003473-29
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
Uni-Koeln-1488
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.